Therapeutic Area: Oncology

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Lavin et al.
Cell
Papers
May 2017
Authors and Affiliates
Yonit Lavin,1,2,3 Soma Kobayashi,1,2,3 Andrew Leader,1,2,3 El-ad David Amir,2,3,9 Naama Elefant,10 Camille Bigenwald,1,2,3 Romain Remark,1,2,3 Robert Sweeney,6,7 Christian D. Becker,4 Jacob H. Levine,11 Klaus Meinhof,4 Andrew Chow,1,2,3 Seunghee Kim-Shulze,2,3,9 Andrea Wolf,6 Chiara Medaglia,10 Hanjie Li,10 Julie A. Rytlewski,12 Ryan O. Emerson,12 Alexander Solovyov,1,3,5,8 Benjamin D. Greenbaum,1,3,5,8 Catherine Sanders,12 Marissa Vignali,12 Mary Beth Beasley,8 Raja Flores,6 Sacha Gnjatic,2,3,5,9 Dana Pe’er,11 Adeeb Rahman,2,3,7,9 Ido Amit,10 and Miriam Merad1,2,3,9 1Department of Oncological Sciences 2The Precision Immunology Institute 3Tisch Cancer Institute 4Division of Pulmonology 5Division of Hematology/Oncology 6Department of Thoracic Surgery 7Department of Genetics and Genomic Sciences 8Department of Pathology 9Human Immune Monitoring Center Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA 10Department of Immunology, Weizmann Institute, Rehovot 76100, Israel 11Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA 12Adaptive Biotechnologies Inc., Seattle, WA 98102, USA

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

Snyder et al.
Papers
PLOS Medicine
May 2017
immuneAccess
Authors and Affiliates
Alexandra Snyder1,2, Tavi Nathanson3, Samuel A. Funt1,2, Arun Ahuja3, Jacqueline Buros Novik3, Matthew D. Hellmann1,2, Eliza Chang3, Bulent Arman Aksoy3, Hikmat Al-Ahmadie4, Erik Yusko5, Marissa Vignali5, Sharon Benzeno5, Mariel Boyd1, Meredith Moran1, Gopa Iyer1,2, Harlan S. Robins5,6, Elaine R. Mardis7, Taha Merghoub1, Jeff Hammerbacher3, Jonathan E. Rosenberg1, Dean F. Bajorin1,2 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America, 2Department of Medicine, Weill Cornell Medical College, New York, New York, United States of America, 3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America, 4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America, 5Adaptive Biotechnologies, Seattle, Washington, United States of America, 6Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 7Department of Pediatrics, Institute for Genomic Medicine, The Research Institute at Nationwide Children’s Hospital, The Ohio State University College of Medicine, Columbus, Ohio, United States of America

Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy

Zhang et al.
Papers
Science Advances
May 2017
Authors and Affiliates
Jingyu Zhang,1,2 Dai Liu,3 Guangfu Li,3 Kevin F. Staveley-O’Carroll,3 Julie N. Graff,4 Zihai Li,1,5 Jennifer D. Wu1,5 1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. 2CanCure LLC, Everett, WA 98208, USA. 3School of Medicine, University of Missouri, Columbia, MO 65211, USA. 4Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA. 5Cancer Immunology Program, Hollings Cancer Center, Charleston, SC 29425, USA.

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Huang et al.
Nature
Papers
April 2017
Authors and Affiliates
Alexander C. Huang1,2,3,4, Michael A. Postow5,6, Robert J. Orlowski1,2,3,4, Rosemarie Mick3,4,7, Bertram Bengsch2,4,8, Sasikanth Manne2,8, Wei Xu1,3, Shannon Harmon1,3, Josephine R. Giles2,4,8, Brandon Wenz1,3, Matthew Adamow9, Deborah Kuk10, Katherine S. Panageas10, Cristina Carrera5,11, Phillip Wong9,12, Felix Quagliarello2,8, Bradley Wubbenhorst1,3, Kurt D’Andrea1,3, Kristen E. Pauken2,8, Ramin S. Herati1,2,3, Ryan P. Staupe2,8, Jason M. Schenkel13, Suzanne McGettigan1,3, Shawn Kothari1, Sangeeth M. George2,4,8, Robert H. Vonderheide1,2,3,4, Ravi K. Amaravadi1,3, Giorgos C. Karakousis3,14, Lynn M. Schuchter1,3, Xiaowei Xu3,15, Katherine L. Nathanson1,3,4, Jedd D. Wolchok5,12, Tara C. Gangadhar1,3, and E. John Wherry2,3,4,8 1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, Pennsylvania, USA. 5Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 6Weill Cornell Medical College, New York, New York, USA. 7Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 8Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 9Immune Monitoring Facility, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 10Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 11Department of Dermatology, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain. 12Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, New York, USA. 13Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA. 14Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 15Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer

Stevanović et al.
Papers
Science
April 2017
Authors and Affiliates
Sanja Stevanović,1 Anna Pasetto,2 Sarah R. Helman,1 Jared J. Gartner,2 Todd D. Prickett,2 Bryan Howie,3 Harlan S. Robins,3,4 Paul F. Robbins,2 Christopher A. Klebanoff,5,6 Steven A. Rosenberg,2 Christian S. Hinrichs1 1Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD 20892, USA. 2Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA. 3Adaptive Biotechnologies, Seattle, WA 98102, USA. 4Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 5Center for Cell Engineering and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. 6Parker Institute for for Cancer Immunotherapy, New York, NY 10065, US

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

Roh et al.
Papers
Science Translational Medicine
March 2017
Authors and Affiliates
Whijae Roh,1,2 Pei-Ling Chen,1,3 Alexandre Reuben,4 Christine N. Spencer,1 Peter A. Prieto,4 John P. Miller,5 Vancheswaran Gopalakrishnan,4 Feng Wang,1 Zachary A. Cooper,1,4 Sangeetha M. Reddy,6 Curtis Gumbs,1 Latasha Little,1 Qing Chang,1 Wei-Shen Chen,1,3 Khalida Wani,7 Mariana Petaccia De Macedo,7,8 Eveline Chen,7 Jacob L. Austin-Breneman,4 Hong Jiang,4 Jason Roszik,1,9 Michael T. Tetzlaff,3 Michael A. Davies,9 Jeffrey E. Gershenwald,4 Hussein Tawbi,9 Alexander J. Lazar,4,7 Patrick Hwu,9 Wen-Jen Hwu,9 Adi Diab,9 Isabella C. Glitza,9 Sapna P. Patel,9 Scott E. Woodman,9 Rodabe N. Amaria,9 Victor G. Prieto,3 Jianhua Hu,10 Padmanee Sharma,11,12 James P. Allison,11 Lynda Chin,13 Jianhua Zhang,14 Jennifer A. Wargo,1,4 P. Andrew Futreal1 1Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2Cancer Biology Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA. 3Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 5Oncology Research for Biologics and Immunotherapy Translation, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 6Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 7Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 8Pathology Department, A.C. Camargo Cancer Center, São Paulo, SP-01509-010, Brazil. 9Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 10Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 11Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 12Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 13University of Texas System, Austin, TX 78701, USA. 14Applied Cancer Science Institute, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis

Lombardo et al.
Blood
Papers
March 2017
immuneAccess
Authors and Affiliates
Katharine A. Lombardo,1,2 David G. Coffey,1,3 Alicia J. Morales,1 Christopher S. Carlson,4 Andrea M. H. Towlerton,1 Sarah E. Gerdts,5 Francis K. Nkrumah,6 Janet Neequaye,7 Robert J. Biggar,8 Jackson Orem,9 Corey Casper,1,3-5,10,11 Sam M. Mbulaiteye,12 Kishor G. Bhatia,12 and Edus H. Warren1,3 1Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA; 2Molecular and Cellular Biology Program and 3Department of Medicine, School of Medicine, University of Washington, Seattle, WA; 4Division of Public Health Sciences and 5Division of Vaccine and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA; 6Noguchi Institute for Medical Research and 7Department of Child Health, Medical School, University of Ghana, Accra, Ghana; 8Institute of Health and Biotechnical Innovation, Queensland University of Technology, Brisbane, QLD, Australia; 9Uganda Cancer Institute, Kampala, Uganda; 10Department of Global Health, School of Medicine, and 11Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA; and 12Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens

Khodadoust et al.
Nature
Papers
March 2017
Authors and Affiliates
Michael S. Khodadoust1, Niclas Olsson2, Lisa E. Wagar3, Ole A. W. Haabeth1, Binbin Chen1,4, Kavya Swaminathan2, Keith Rawson2, Chih Long Liu1, David Steiner5, Peder Lund3, Samhita Rao2, Lichao Zhang2, Caleb Marceau3, Henning Stehr1, Aaron M. Newman1,6, Debra K. Czerwinski1, Victoria E. H. Carlton7, Martin Moorhead7, Malek Faham7, Holbrook E. Kohrt1, Jan Carette3, Michael R. Green1, Mark M. Davis3,8, Ronald Levy1, Joshua E. Elias2 & Ash A. Alizadeh1,6,9 1Department of Medicine, Division of Oncology, Stanford University, Stanford, California 94305, USA. 2Department of Chemical & Systems Biology, Stanford University, Stanford, California 94305, USA. 3Department of Microbiology & Immunology, Stanford University, Stanford, California 94305, USA. 4Department of Genetics, Stanford University, Stanford, California 94305, USA. 5Department of Pathology, Stanford University, Stanford, California 94305, USA. 6Center for Cancer Systems Biology, Stanford University, Stanford, California 94305, USA. 7Adaptive Biotechnologies, South San Francisco, California 94080, USA. 8Howard Hughes Medical Institute, Stanford University, Stanford, California 94305, USA. 9Institute for Stem Cell Biology & Regenerative Medicine, Stanford University, Stanford, California 94305, USA.

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

Juneja et al.
Journal of Experimental Medicine
Papers
March 2017
Authors and Affiliates
Vikram R. Juneja,1,2,5 Kathleen A. McGuire,2,5 Robert T. Manguso,3,6 Martin W. LaFleur,2,5,6 Natalie Collins,4,6,8 W. Nicholas Haining,4,6,8 Gordon J. Freeman,7 and Arlene H. Sharpe2,5 1Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, 2Department of Microbiology and Immunobiology, 3Division of Medical Sciences, and 4Division of Hematology/Oncology, Children's Hospital, Harvard Medical School, Boston, MA 02115, 5Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA 02115, 6Department of Pediatric Oncology and 7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, 8Broad Institute of MIT and Harvard, Cambridge, MA 02142